Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results tomorrow morning. Here’s what investors should know.

Baxter missed analysts’ revenue expectations by 29.8% last quarter, reporting revenues of $2.70 billion, up 3.8% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates and a slight miss of analysts’ full-year EPS guidance estimates.

Is Baxter a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Baxter’s revenue to decline 2.4% year on year to $2.66 billion, improving from the 27.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.52 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings.

Looking at Baxter’s peers in the medical devices & supplies - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.4%, beating analysts’ expectations by 3.3%, and Stryker reported revenues up 10.7%, topping estimates by 1.4%. Boston Scientific traded up 1.5% following the results while Stryker was down 1%.

Read our full analysis of Boston Scientific’s results here and Stryker’s results here.

Investors in the medical devices & supplies - diversified segment have had steady hands going into earnings, with share prices flat over the last month. Baxter’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $39.58 (compared to the current share price of $30.57).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.